I n this issue of Cancer Cytopathology, Manfrin et al. 1 describe the quality performance results of fine-needle aspiration biopsies performed in their Breast Cancer Screening Program in Verona, Italy. Not surprisingly, because they have an integrated radiopathologic program with pathologists on the
Fine needle aspiration techniques for the characterization of breast cancers
โ Scribed by Britt-Marie Ljung; Karen Chew; Guoren Deng; Kouji Matsumura; Fred Waldman; Helene Smith
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 683 KB
- Volume
- 74
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Fine needle aspiration biopsy (FNAB) is a well established method for diagnosing breast lesions, including cancers. FNAB does not require surgery and uses only a small amount of material. FNAB can also be used to acquire material for special studies. This is especially useful with small tumors (4 cm) when most of the material is needed to make a histologic diagnosis. Immunostaining techniques can be used on FNABs to investigate proliferation by bromodeoxyuridine uptake or Ki-67 labeling. Immunostaining techniques can also be used to identify oncoprotein expression, such as of p53. Fluorescence in situ hybridization is a technique that can be used to gather cytogenetic information directly from interphase tumor cells and is well suited for use with FNAB material because the harvested nuclei are intact and no cumbersome dissociation processing is needed. Flow cytometric techniques can be applied to FNAB material to study DNA content and S-phase fraction. Material acquired by FNAB can also be analyzed by the polymerase chain reaction followed by mutation detection. In this report, the authors show the applicability of these various analytic approaches to FNAB material from primary breast cancers. They show that it is essential that the FNAB harvest is representative, ample, and well prepared for the success of these studies. Cancer 1994; 74:lOOO-5.
๐ SIMILAR VOLUMES
Xcyt) was used to categorize 56 (37 benign and 19 Hospitals and Clinics, Iowa City, Iowa. malignant) breast FNAs diagnosed as ''indeterminate'' and the computer diagnosis 2 Departments of Surgery and Human Oncolcompared with the surgical biopsy. For each case, an operator chose a group of ogy, Univ
Selection of surrogate endpoint biomarkers (SEBs) and appropriate study design are two of the main challenges in evaluating potential chemopreventive agents. In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated t
all fine-needle aspirates (FNA) performed on the male breast at The University of Texas M. D. Anderson Cancer Center from 1985 to 1992 were reviewed, totaling 64. Thepatients'ages ranged from 19 to 86 years, with a mean of56years. Thirty-three patients had a history of an extramammary malignancy. Th